These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 35498884

  • 1. Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease.
    Naranjo J, Furlano M, Torres F, Hernandez J, Pybus M, Ejarque L, Cordoba C, Guirado L, Ars E, Torra R.
    Clin Kidney J; 2022 May; 15(5):912-921. PubMed ID: 35498884
    [Abstract] [Full Text] [Related]

  • 2. Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.
    Borrego Utiel FJ, Esteban de la Rosa RJ, Merino García E, Medina Benítez A, Polo Moyano A, Moriana Domínguez C, Morales García AI, Bravo Soto JA.
    Am J Nephrol; 2021 May; 52(8):630-641. PubMed ID: 34518464
    [Abstract] [Full Text] [Related]

  • 3. Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study.
    Park HC, Hong Y, Yeon JH, Ryu H, Kim YC, Lee J, Kim YH, Chae DW, Chung W, Ahn C, Oh KH, Oh YK.
    Kidney Res Clin Pract; 2022 Jul; 41(4):432-441. PubMed ID: 35286789
    [Abstract] [Full Text] [Related]

  • 4. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC, Kim J, Cho A, Kim DH, Lee YK, Ryu H, Kim H, Oh KH, Oh YK, Hwang YH, Lee KB, Kim SW, Kim YH, Lee J, Ahn C, KNOW-CKD Investigators Group.
    J Korean Med Sci; 2020 Jun 08; 35(22):e165. PubMed ID: 32508065
    [Abstract] [Full Text] [Related]

  • 5. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE, HALT Investigators.
    Nephrol Dial Transplant; 2017 Nov 01; 32(11):1857-1865. PubMed ID: 27484667
    [Abstract] [Full Text] [Related]

  • 6. Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging.
    Akbari P, Nasri F, Deng SX, Khowaja S, Lee SH, Warnica W, Lu H, Rattansingh A, Atri M, Khalili K, York P.
    Clin J Am Soc Nephrol; 2022 Jun 01; 17(6):827-834. PubMed ID: 35383043
    [Abstract] [Full Text] [Related]

  • 7. Germline Mutations for Kidney Volume in ADPKD.
    Kataoka H, Yoshida R, Iwasa N, Sato M, Manabe S, Kawachi K, Makabe S, Akihisa T, Ushio Y, Teraoka A, Tsuchiya K, Nitta K, Mochizuki T.
    Kidney Int Rep; 2022 Mar 01; 7(3):537-546. PubMed ID: 35257066
    [Abstract] [Full Text] [Related]

  • 8. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
    Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, CRISP Investigators.
    J Am Soc Nephrol; 2015 Jan 01; 26(1):160-72. PubMed ID: 24904092
    [Abstract] [Full Text] [Related]

  • 9. Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression.
    Furlano M, Loscos I, Martí T, Bullich G, Ayasreh N, Rius A, Roca L, Ballarín J, Ars E, Torra R.
    Am J Nephrol; 2018 Jan 01; 48(4):308-317. PubMed ID: 30347391
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study.
    Lai S, Mastroluca D, Perrotta AM, Muscaritoli M, Lucciola S, Felli MP, Izzo P, Rotondi S, Izzo S, Tartaglione L, Belli R, Ramaccini C, Izzo L, De Intinis C, Panebianco V, Mazzaferro S.
    J Nephrol; 2024 Jul 05. PubMed ID: 38969871
    [Abstract] [Full Text] [Related]

  • 11. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT, Torres VE.
    Am J Kidney Dis; 2021 Aug 05; 78(2):282-292. PubMed ID: 33705818
    [Abstract] [Full Text] [Related]

  • 12. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.
    Bais T, Geertsema P, Knol MGE, van Gastel MDA, de Haas RJ, Meijer E, Gansevoort RT, DIPAK Consortium.
    Clin J Am Soc Nephrol; 2024 May 01; 19(5):591-601. PubMed ID: 38407866
    [Abstract] [Full Text] [Related]

  • 13. Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease.
    Rocchetti MT, Pesce F, Matino S, Piscopo G, di Bari I, Trepiccione F, Capolongo G, Perniola MA, Song X, Khowaja S, Haghighi A, Peters D, Paolicelli S, Pontrelli P, Netti GS, Ranieri E, Capasso G, Moschetta M, Pei Y, Gesualdo L, (Studio PRE. MED. (MEDicina di PREcisione) Prog.n.F/050065/01-02/X32).
    J Nephrol; 2023 May 01; 36(4):987-997. PubMed ID: 36342644
    [Abstract] [Full Text] [Related]

  • 14. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):645-652. PubMed ID: 28992127
    [Abstract] [Full Text] [Related]

  • 15. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H, Park HC, Oh YK, Sangadi I, Wong A, Mei C, Ecder T, Wang AY, Kao TW, Huang JW, Rangan GK, Ahn C.
    BMJ Open; 2020 Feb 06; 10(2):e034103. PubMed ID: 32034027
    [Abstract] [Full Text] [Related]

  • 16. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
    Riyahi S, Dev H, Blumenfeld JD, Rennert H, Yin X, Attari H, Barash I, Chicos I, Bobb W, Donahue S, Prince MR.
    J Magn Reson Imaging; 2021 Feb 06; 53(2):564-576. PubMed ID: 32969110
    [Abstract] [Full Text] [Related]

  • 17. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Feb 06; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 18. Clinical Characteristics of Rapid Progression in Asia-Pacific Patients With ADPKD.
    Oh YK, Ryu H, Ahn C, Park HC, Ma Y, Xu D, Ecder T, Kao TW, Huang JW, Rangan GK, RAPID-ADPKD Study Group.
    Kidney Int Rep; 2023 Sep 06; 8(9):1801-1810. PubMed ID: 37705904
    [Abstract] [Full Text] [Related]

  • 19. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
    Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE.
    Kidney Int Rep; 2016 Nov 06; 1(4):213-220. PubMed ID: 29142926
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.